India’s Top Deck Backs Patent Box Policies, Four-Prong Strategy
Generics For Growth, Innovation For Future
Executive Summary
C-suite executives from Sun Pharma, Zydus, Dr Reddy’s, Biocon, Piramal and Bharat Serums discuss future growth drivers as the generics opportunity shrinks. Favorable patent box policies, open-source innovation and areas like gene therapy and orphan diseases feature among ideas thrown up.
You may also be interested in...
Global R&D Heads Talk Superbugs, PROTACs And More
A panel of R&D experts from Merck’s EMD Serono, Boehringer Ingelheim, Takeda and Hilleman Labs discuss technologies like PROTACs and multi-specific antibodies, a superbug that could cause more damage than COVID-19 and the need for harmonized regulation that recognizes risk is essential to discovery
India CEOs On Automated Plants, New Modalities, Tackling 'The Great Talent Reshuffle'
The top leadership of Cipla, Dr Reddy’s Laboratories, Zydus Cadila, Sun Pharmaceutical Industries and Lupin discuss automation roadmaps, strategies for a play in new modalities and talent acquisition and retention amid the global "great resignation."
Zydus Claims Top Spot In India Biosimilars With Kadcyla, Sees 40-50% Growth
Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.